{"id":760237,"date":"2023-05-24T09:55:04","date_gmt":"2023-05-24T13:55:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/"},"modified":"2023-05-24T09:55:04","modified_gmt":"2023-05-24T13:55:04","slug":"renovorx-to-present-at-the-ld-micro-invitational-xiii-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/","title":{"rendered":"RenovoRx to Present at the LD Micro Invitational XIII Conference"},"content":{"rendered":"

<\/p>\n

RenovoRx to Present at the LD Micro Invitational XIII Conference<\/b><\/p>\n

LOS ALTOS, Calif.–(BUSINESS WIRE<\/a>)–RenovoRx, Inc<\/a>. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.<\/p>\n

\nMr. Bagai will provide a corporate update including recently announced positive interim data<\/a> for the Company\u2019s ongoing open label, randomized Phase III TIGeR-PaC clinical trial to treat Locally Advanced Pancreatic Cancer (LAPC). Interim data demonstrated that patients on the RenovoGem\u2122 test arm demonstrated a 60% survival benefit and 65% side effect reduction versus systemic chemotherapy.<\/p>\n

Presentation Details:<\/b><\/p>\n

Date: <\/b>Tuesday, June 6, 2023
\n
Time: <\/b>1:00 p.m. \u2013 1:25 p.m. PT
\n
Registration\/Webcast Link: <\/b>https:\/\/ldinv13.sequireevents.com\/<\/a><\/p>\n

\nFor more information about the conference, or to schedule a one-on-one meeting with RenovoRx\u2019s management team, please contact your appropriate LD Micro representatives, or email renovorx@kcsa.com<\/a>.<\/p>\n

\nA webcast of the event will be available for a limited time on the Events page<\/a> in the Investors<\/a> section of the Company\u2019s website<\/a>.<\/p>\n

About RenovoGem<\/b><\/p>\n

\nRenovoGem\u2122 is the first drug-device combination product candidate that utilizes the RenovoTAMP\u00ae<\/sup> therapy platform via pressure-mediated delivery technology to deliver gemcitabine, an FDA-approved systemic chemotherapy, locally across the arterial wall to bathe tumor tissue in the chemotherapy. RenovoGem is currently being evaluated in the Phase III TIGeR-PaC clinical trial study in Locally Advanced Pancreatic Cancer (LAPC) patients. The Company plans to investigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA) in a clinical trial, which is anticipated to begin in the first half of 2023. RenovoGem\u2122 is currently under investigation for the intra-arterial delivery of gemcitabine and has not been approved for commercial sale.<\/p>\n

About RenovoRx, Inc.<\/b><\/p>\n

\nRenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae<\/sup>) therapy platform aims to avoid the harsh side effects typical of the current standard of care, or systemic delivery methods, thus improving patient well-being and, potentially extension of life, so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and clinical use, with the goal of improving their safety, tolerance, and widening their therapeutic window by providing more targeted delivery at the location of the tumor tissue. RenovoRx\u2019s lead product candidate, RenovoGem\u2122, is a combination of gemcitabine and its patented delivery system, RenovoCath\u00ae<\/sup>, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase III TIGeR-PaC clinical trial for the treatment of LAPC.<\/p>\n

\nRenovoRx\u2019s patent portfolio for its therapy platform and product candidates includes eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma).<\/p>\n

\nLearn more by visiting the RenovoRx website<\/a> or following RenovoRx on Facebook<\/a>, LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230524005310\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
KCSA Strategic Communications
\n
Valter Pinto or Jack Perkins
\n
T:212-896-1254
\n
renovorx@kcsa.com<\/a><\/p>\n

Media Contact:
\n<\/b>
Kimberly Ha
\n
T: 9172915744
\n
kimberly.ha@kkhadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

RenovoRx to Present at the LD Micro Invitational XIII Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Mr. Bagai will provide a corporate update including recently announced positive interim data for the Company\u2019s ongoing open label, randomized Phase III TIGeR-PaC clinical trial to treat Locally Advanced Pancreatic Cancer (LAPC). Interim data demonstrated that patients on the RenovoGem\u2122 test arm demonstrated a 60% survival benefit and 65% side effect reduction versus systemic chemotherapy. Presentation Details: Date: Tuesday, … <\/p>\n

Continue reading “RenovoRx to Present at the LD Micro Invitational XIII Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760237","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RenovoRx to Present at the LD Micro Invitational XIII Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Mr. Bagai will provide a corporate update including recently announced positive interim data for the Company\u2019s ongoing open label, randomized Phase III TIGeR-PaC clinical trial to treat Locally Advanced Pancreatic Cancer (LAPC). Interim data demonstrated that patients on the RenovoGem\u2122 test arm demonstrated a 60% survival benefit and 65% side effect reduction versus systemic chemotherapy. Presentation Details: Date: Tuesday, … Continue reading "RenovoRx to Present at the LD Micro Invitational XIII Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-24T13:55:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RenovoRx to Present at the LD Micro Invitational XIII Conference\",\"datePublished\":\"2023-05-24T13:55:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/\",\"name\":\"RenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-24T13:55:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RenovoRx to Present at the LD Micro Invitational XIII Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/","og_locale":"en_US","og_type":"article","og_title":"RenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk","og_description":"RenovoRx to Present at the LD Micro Invitational XIII Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Mr. Bagai will provide a corporate update including recently announced positive interim data for the Company\u2019s ongoing open label, randomized Phase III TIGeR-PaC clinical trial to treat Locally Advanced Pancreatic Cancer (LAPC). Interim data demonstrated that patients on the RenovoGem\u2122 test arm demonstrated a 60% survival benefit and 65% side effect reduction versus systemic chemotherapy. Presentation Details: Date: Tuesday, … Continue reading \"RenovoRx to Present at the LD Micro Invitational XIII Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-24T13:55:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RenovoRx to Present at the LD Micro Invitational XIII Conference","datePublished":"2023-05-24T13:55:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/","name":"RenovoRx to Present at the LD Micro Invitational XIII Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-24T13:55:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005310r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-ld-micro-invitational-xiii-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RenovoRx to Present at the LD Micro Invitational XIII Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760237"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760237\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}